Veeva Systems announced it has acquired Veracity Logic, a provider of cloud software for randomization and trial supply management (RTSM). The Veracity Logic team will join Veeva to deliver industry-leading software and services, helping companies simplify complex processes and expedite clinical trials.
Also Read: Medo AI and Medical Imaging Consultants announce partnership to simplify diagnostic ultrasound imaging.
The solution, offered as Veevasystems RTSM, delivers fast setup timelines and a configurable feature set to meet a broad array of randomization and supply needs. It has supported over 175 trials with sites in 60 countries, covering a range of trial designs and complexities across all therapeutic areas in pharma/biotech, medical device, and diagnostics.
“We are pleased to have the Veracity Logic team join Veeva and look forward to bringing RTSM excellence to our customers,” said Jim Reilly, vice president, Vault R&D and Quality at Veeva Systems. “This expands Veeva’s clinical offering with flexible and user-friendly RTSM capabilities.”
Veevasystems is committed to continuity and openness for Veeva RTSM customers and Veeva’s RTSM partners including, Almac Group, S-CLINICA, Signant Health, Suvoda, and 4G Clinical. New and existing customers will have the choice to integrate Veeva RTSM with any EDC system and to use Veeva EDC with any RTSM system.
“We are excited to join Veevasystems. This acquisition is great for our customers and employees,” said Steve Zimmerman, Veracity Logic founder. “Joining Veeva allows us to scale our solution to a wider market while continuing to deliver customer success.”
Veevasystems RTSM will be led by founder Steve Zimmerman as general manager, current President David Goldston as vice president of sales, and Natalie Townsend as vice president of strategy.
Veevasystems is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs.